Mereo BioPharma Group plc (Mereo) (MREO) News
Filter MREO News Items
MREO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MREO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MREO News From Around the Web
Below are the latest news stories about MEREO BIOPHARMA GROUP PLC that investors may wish to consider to help them evaluate MREO as an investment opportunity.
Mereo BioPharma Provides Update on Lead Clinical ProgramsOrbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final decision in first quarter 2025 LONDON, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical comp |
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceLONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 8:15am PT / 04:15pm GMT. A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereo |
Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now?We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Mereo BioPharma Group plc (NASDAQ:MREO) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit […] |
Mereo BioPharma initiated with a Buy at JefferiesJefferies analyst Maury Raycroft initiated coverage of Mereo BioPharma (MREO) with a Buy rating and $7 price target The company’s lead asset setrusumab is in Phase III for osteogenesis imperfecta, the analyst tells investors in a research note. The firm believes the second interim study will succeed and says the first interim “has a chance too.” With this near-term success, a launch with no near-term competition and “healthy royalties,” Jefferies sees shares upside. Published first on TheFly – t |
Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89%Jefferies expressed confidence in setrusumab's Phase 3 trial results, developed with Ultragenyx. |
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceLONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:30am ET / 03:30pm GMT. A live audio webcast of the presentation can be accessed through the Investors section of the Company’s web |
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateSetrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash a |
Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds?In this article, we will look at the 8 Hot Penny Stocks To Invest In According to Hedge Funds. Let’s look at where Mereo BioPharma Group (MREO) stands against other hot penny stocks. Financial markets are betting that the Federal Reserve’s half-point interest rate cut in September will be followed by slower and smaller moves due […] |
Mereo BioPharma Group plc (MREO): A Bull Case TheoryWe came across a bullish thesis on Mereo BioPharma Group plc (MREO) on Raging Bull Investments’ Substack by Jake LaMotta. In this article we will summarize the bulls’ thesis on MREO. Mereo BioPharma Group plc (MREO) share was trading at $3.95 as of Sept 17th. Mereo BioPharma is positioning itself as a key player in rare diseases, […] |
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare ConferenceLONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST. A live audio webcast can be accessed through the Investors section of the Company’s website at www.me |